RxDoctor Payments Data

Shahid Bashir, MD

Pulmonary Disease · Springfield, OHNPI 1982751244

Payments from drug & device makers

$926in general payments, 2019–2025

Across 61 payments — averaging $15.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$302
  • GSK$222
  • Sanofi$96
  • Boehringer Ingelheim$64
  • Genentech USA, Inc.$53
  • Actelion Pharmaceuticals US, Inc.$48
  • plus $141 from 10 others

What the payments were for

  • Food & beverage$85692%
  • Education$708%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$926 in reported general payments places this provider in the 40th percentile of 571 pulmonary disease providers in Ohio.

See all pulmonary disease providers in Ohio

Medicare billing

Part B allowed, 2024
$102,315
Medicare patients
401
Services billed
1,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter471$366,838
OfevNintedanib Esylate12$159,825
Breo ElliptaFluticasone/Vilanterol347$158,057
Spiriva RespimatTiotropium Bromide98$65,389
SymbicortBudesonide/Formoterol Fumarate166$48,805
Breztri AerosphereBudesonide/Glycopyr/Formoterol70$45,083
Combivent RespimatIpratropium/Albuterol Sulfate79$42,558
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr62$34,212
Bevespi AerosphereGlycopyrrolate/Formoterol Fum38$20,654
Incruse ElliptaUmeclidinium Bromide49$20,141
Advair HfaFluticasone Propion/Salmeterol47$17,507
Albuterol Sulfate HfaAlbuterol Sulfate446$16,674
Atrovent HfaIpratropium Bromide23$16,612
DuleraMometasone/Formoterol23$8,572
Coly-Mycin M ParenteralColistin (Colistimethate Na)11$8,390

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$222$584,487945 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat$64$267,772189 claims
AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere$302$114,541274 claims
MerckDulera$13$8,57223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 571 pulmonary disease providers in Ohio.

Other pulmonary disease in Springfield

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →